Legal Representation
Attorney
Maury M. Tepper, III
USPTO Deadlines
Application History
32 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 3, 2023 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Aug 3, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Aug 3, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Aug 3, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Aug 3, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Aug 3, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jun 26, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 26, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Nov 22, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 18, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 18, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 18, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 24, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 29, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 29, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 9, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 20, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 20, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Feb 20, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Feb 20, 2022 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Feb 20, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Feb 20, 2022 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Feb 19, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 20, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 20, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 20, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 30, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 30, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 30, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 29, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 11, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 9, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for gene therapy and gene editing; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; viral vectors, non-viral vectors, gene therapy vectors all for medical purposes in gene therapy; biotechnological platform technology, namely, biological nanoparticles for gene delivery to biological cells that includes adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; drug delivery agents consisting of compounds comprised of proteins in the form of capsids and particles that facilitate the delivery of a wide range of pharmaceuticals; drug delivery agents, in the form of injectable solutions, intravenous fluids, intracerebral solutions, intrathecal solutions, intracisternal solutions, intraocular solutions, intranasal solutions, intratracheal solutions, intraarterial solutions, intramuscular solutions, and medicinal infusions in that facilitate the delivery of capsids and particles used for delivery of gene therapy
Class 042
medical and scientific research in the fields of gene therapy and gene editing; pharmaceutical research services; pharmaceutical drug development services; custom development of biochemical reagents and biological nanoparticles, namely, therapeutic compositions that feature adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy
Additional Information
Pseudo Mark
SAVVY
Classification
International Classes
005
042